Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Blood

• Publication date

  2010-10-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2010-05-282780PMID 20628145PMCID PMC2995356
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis

  2010cited by this paper
• Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

  2010cited by this paper
• Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome.

  2010cited by this paper
• Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

  2010cited by this paper
• Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival.

  2009cited by this paper
• PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

  2009cited by this paper
• Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma.

  2009cited by this paper
• Conveying glycan information into T‐cell homeostatic programs: a challenging role for galectin‐1 in inflammatory and tumor microenvironments

  2009cited by this paper
• Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

  2009cited by this paper
• The biology of Hodgkin's lymphoma

  2009cited by this paper
• Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities.

  2009cited by this paper
• Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

  2008cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth

  2008cited by this paper
• IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection

  2008cited by this paper
• Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

  2008cited by this paper
• Analyzing real-time PCR data by the comparative CT method

  2008cited by this paper
• Primary mediastinal (thymic) large B-cell lymphoma

  2008cited by this paper
• B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression

  2008cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas

  2008cited by this paper
• Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer.

  2008cited by this paper
• Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.

  2007cited by this paper
• Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

  2007cited by this paper
• Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

  2007cited by this paper
• Programmed Death 1 Ligand (PD-L) 1 and PD-L2 Limit Autoimmune Kidney Disease: Distinct Roles1

  2007cited by this paper
• WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

  2007cited by this paper
• The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma

  2007cited by this paper
• RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma.

  2007cited by this paper
• Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

  2007cited by this paper
• A faster circular binary segmentation algorithm for the analysis of array CGH data

  2007cited by this paper
• Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma

  2007cited by this paper
• PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

  2007cited by this paper
• Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

  2007cited by this paper
• Programmed Death 1 Ligand (PD-L) 1 and PD-L2 Limit Autoimmune Kidney Disease: Distinct Roles

  2007cited by this paper
• Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation

  2006cited by this paper
• Interferon regulatory factor‐1 is prerequisite to the constitutive expression and IFN‐γ‐induced upregulation of B7‐H1 (CD274)

  2006cited by this paper
• SD-1029 Inhibits Signal Transducer and Activator of Transcription 3 Nuclear Translocation

  2006cited by this paper
• Holes in SOCS in primary mediastinal large B-cell lymphoma

  2005cited by this paper
• TOUCAN 2: the all-inclusive open source workbench for regulatory sequence analysis

  2005cited by this paper
• Interleukin‐10 and the immune response against cancer: a counterpoint

  2005cited by this paper
• Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation.

  2005cited by this paper
• Immunotherapeutic Potential of B7-DC (PD-L2) Cross-Linking Antibody In Conferring Antitumor Immunity

  2004cited by this paper
• Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma.

  2004cited by this paper
• Circular binary segmentation for the analysis of array-based DNA copy number data.

  2004cited by this paper
• Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma

  2003cited by this paper
• Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses

  2003cited by this paper
• The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

  2003cited by this paper
• Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.

  2002cited by this paper
• Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

  2002cited by this paper
• Gain of chromosome arm 9p is characteristic of primary mediastinal b‐cell lymphoma (MBL): Comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line

  2001cited by this paper
• Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells.

  2000cited by this paper
• A compilation of composite regulatory elements affecting gene transcription in vertebrates.

  1995cited by this paper

• Nivolumab + Doxorubicin, Vinblastine, and Dacarbazine in HIV-Associated Advanced-Stage Classic Hodgkin Lymphoma

  2026cites this paper
• Hi-C for genome-wide detection of enhancer-hijacking rearrangements in routine lymphoid cancer biopsies.

  2026cites this paper
• Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysis.

  2026influential citation
• Emerging Biomaterials Blocking PD‐1/PD‐L1 Pathway for Cancer Therapy

  2026cites this paper
• Pre-treatment endocrine-nutritional signatures predict clinical benefit from PD-1/PD-L1 blockade in hematologic malignancies.

  2026cites this paper
• Clinical Potential of Copy Number Aberration as a Diagnostic and Prognostic Biomarker in Lymphoma

  2025cites this paper
• Epstein-Barr virus-associated lymphomas: biology, molecular genomics and precision oncology

  2025cites this paper
• Druggable genome CRISPR screening identifies the KEAP1/NRF2 axis as a mediator of PD-L1 expression

  2025cites this paper
• SOHO State of the Art Updates and Next Questions | Latest Advances in the Management of Primary Mediastinal B-Cell Lymphoma.

  2025cites this paper
• Лечение пациентов с рецидивами и рефрактерным течением первичной медиастинальной (тимической) В-крупноклеточной лимфомы: собственные данные и обзор литературы

  2025cites this paper
• Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics

  2025cites this paper
• Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma

  2025cites this paper
• Xq24/IL13RA1 aberrations as key drivers of female bias in primary mediastinal large B‐cell lymphoma

  2025cites this paper
• TNF-α and IFN-γ modulate the evasion of the immune response in primary mediastinal B-cell lymphoma.

  2025cites this paper
• Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response

  2025cites this paper
• Molecular biology of the novel anticancer medications: a focus on kinases inhibitors, biologics and CAR T-cell therapy

  2025cites this paper
• Large B cell lymphoma microenvironment archetype profiles.

  2025cites this paper
• Loss of MNX1 Sensitizes Tumors to Cytotoxic T Cells by Degradation of PD‐L1 mRNA

  2025cites this paper
• The Safety and Efficacy of Immune Checkpoint Blockade in Children, Adolescents, and Young Adults: A Systematic Review and Meta-Analysis

  2025cites this paper
• Flow Cytometry for B-Cell Non-Hodgkin and Hodgkin Lymphomas

  2025cites this paper
• Modern concepts in the treatment of classical Hodgkin lymphoma in children and adolescents

  2025cites this paper
• Recent advances in understanding and management of intravascular large B-cell lymphoma

  2025cites this paper
• Complex regulatory network of programmed death-ligand 1 in cancer: Cancer immunomodulation from molecular mechanisms to clinical applications

  2025cites this paper
• Advanced aggressive clinical features may be associated with immune dysfunction in patients with HIV-positive Hodgkin lymphoma in the cART era: a multicenter study from China

  2025cites this paper
• Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies

  2025cites this paper
• Is escalated BEACOPP dead? Rethinking standards in hodgkin lymphoma treatment

  2025cites this paper
• Hodgkin Lymphoma Classification—From Historical Concepts to Current Refinements

  2025cites this paper
• An Unusual Presentation of T-cell/Histiocyte-Rich B-cell Lymphoma: A Diagnostic Challenge

  2025cites this paper
• Intratumoral heterogeneity and immunotherapy resistance: clinical implications.

  2025cites this paper
• Genomic Taxonomy of Aggressive B-Cell Lymphoid Neoplasms.

  2025cites this paper
• Advances in PD-1/PD-L1 inhibitor combinations with standard therapies for hematological malignancies

  2025cites this paper
• Redefining the Spectrum of EBV-Positive Diffuse Large B-Cell Lymphoma and EBV-Positive Classic Hodgkin Lymphoma.

  2025cites this paper
• Molecular carcinogenesis in Hodgkin lymphoma: Interplay between B lymphocyte mutations and NF-κB pathway dysregulation.

  2025cites this paper
• Mediastinal Gray Zone Lymphomas: Diagnostic Challenges, Clinicopathologic Overlap, and Emerging Management Strategies

  2025cites this paper
• Spatial Analysis of the Tumor Microenvironment in Diffuse Large B-cell Lymphoma Reveals Clinically Relevant Cell Interactions and Recurrent Cellular Neighborhoods

  2025cites this paper
• PDL1 Gene Gain Predicts an Unfavorable Prognosis in HIV-Positive Primary Central Nervous System Lymphoma

  2025cites this paper
• Long‐Term Outcomes and Management Strategies With DA‐R‐EPOCH in Primary Mediastinal B‐Cell Lymphoma: Insights From a Single‐Center Experience

  2025cites this paper
• High-accuracy Detection of PD-L1 3’-UTR Disruption by Immunohistochemistry and Fluorescence in Situ Hybridization on Formalin-fixed Paraffin-embedded Sections

  2025cites this paper
• The role of UBR2 in triple-negative breast cancer and its implications for immune checkpoint blockade therapy

  2025cites this paper
• Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors

  2025cites this paper
• Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas

  2025cites this paper
• PD-L1/PD-L2 genetic profile in the molecular cytogenetic classification of classic Hodgkin lymphoma

  2025cites this paper
• Epstein–Barr Infection, Hodgkin’s Lymphoma, and the Immune System: Insights into the Molecular Mechanisms Facilitating Immune Evasion

  2025cites this paper
• The PD-L1 promoter methylatıon predıcts gene and proteın expressıon levels ın urothelıal carcınoma.

  2025cites this paper
• High PD-L1 Expression in HRS Cells and Macrophages in Tumor Immune Microenvironment Is Associated with Adverse Outcome and EBV Positivity in Classical Hodgkin Lymphoma

  2025cites this paper
• p53/PD-L1 co-expression predicts poor prognosis in diffuse large B-cell lymphoma

  2025cites this paper
• The Epstein-Barr Virus in Classical Hodgkin Lymphoma: Pathogenesis, Immunobiology, and Therapeutic Implications.

  2025cites this paper
• JAK3A573V and JAK3M511I mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3/PD-L1 pathway

  2025cites this paper
• Optimally Delivered R-da-EPOCH Versus R-CHOP-21 in Primary Mediastinal Large B-Cell Lymphoma: A Real-Life Comparison in a Single Academic Center

  2025cites this paper
• Precision Oncology in Hodgkin’s Lymphoma: Immunotherapy and Emerging Therapeutic Frontiers

  2025cites this paper
• Clinicopathological Study of Hodgkin Lymphoma in Relation to Programmed Death-Ligand 1 (PD-L1) Expression and Epstein-Barr Virus (EBV) Status

  2025cites this paper
• Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors

  2025cites this paper
• PIM kinase inhibition attenuates pro-tumoral and immunosuppressive functions of macrophages in classic Hodgkin lymphoma

  2025cites this paper
• Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies.

  2025cites this paper
• Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironment

  2025cites this paper
• The pediatric approach to Hodgkin lymphoma.

  2024cites this paper
• The biology of classical Hodgkin lymphoma.

  2024cites this paper
• Partial remission with sintilimab monotherapy in a patient carrying a CD274 amplification in refractory diffuse large B‑cell lymphoma: A case report

  2024cites this paper
• Regulatory mechanisms of PD-1/PD-L1 in cancers

  2024cites this paper
• Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects

  2024cites this paper
• Emerging immunotherapies in the Hodgkin lymphoma armamentarium

  2024cites this paper
• Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment

  2024cites this paper
• Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.

  2024cites this paper
• Programmed cell death-ligand 2: new insights in cancer

  2024cites this paper
• TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma.

  2024cites this paper
• Research progress on the mechanism of common inflammatory pathways in the pathogenesis and development of lymphoma

  2024influential citation
• Pinpointing Functionally Relevant miRNAs in Classical Hodgkin Lymphoma Pathogenesis

  2024cites this paper
• Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan

  2024cites this paper
• Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison

  2024cites this paper
• Metabolic instruction of the graft-versus-leukemia immunity

  2024cites this paper
• Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies

  2024cites this paper
• Transmembrane domain–driven PD-1 dimers mediate T cell inhibition

  2024cites this paper
• A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma

  2024cites this paper
• T cell states, repertoire and function in classical Hodgkin lymphoma revealed through single-cell analyses.

  2024cites this paper
• Epstein-Barr Virus Orchestrates Spatial Reorganization and Immunomodulation within the Classic Hodgkin Lymphoma Tumor Microenvironment

  2024cites this paper
• Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphoma

  2024influential citation
• Primary Large B-cell Lymphomas of Immune-Privileged Sites.

  2024cites this paper
• Immunotherapy in the Management of Hodgkin Lymphoma: Time for Immunotherapy for All?

  2024cites this paper
• A Case of Durvalumab-induced Steroid-refractory Myocarditis, Myasthenia Gravis, and Myositis Successfully Treated with Infliximab

  2024cites this paper
• Interferon-ε loss is elusive 9p21 link to immune-cold tumors, resistant to immune-checkpoint therapy and endogenous CXCL9/10 induction.

  2024cites this paper
• Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy

  2024cites this paper
• Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma

  2024cites this paper
• Getting the right combination to break the epigenetic code

  2024cites this paper
• Successful Treatment of a Patient Presenting with Simultaneous Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma: A Case Report

  2024cites this paper
• Aberrantly Expressed Mitochondrial Lipid Kinase, AGK Activates JAK2-Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy.

  2024cites this paper
• Analysis of microsatellite instability in primary mediastinal large B-cell lymphoma: Focus on PD-L1/PD-L2 and CIITA

  2024cites this paper
• Research Progress of Immune Checkpoint Inhibitors in the Treatment of Hepatocellular Carcinoma

  2024cites this paper
• PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies

  2024cites this paper
• Primary Mediastinal Large B-cell Lymphoma From the Clinic to Genomics: Insights for Pathologists.

  2024cites this paper
• Therapy for Hodgkin's Lymphoma - Can It Get Any Better?

  2024cites this paper
• Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma

  2024cites this paper
• Advances in Hodgkin lymphoma research.

  2024cites this paper
• Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma.

  2024cites this paper
• Immune Cell Influence on Diffuse Large B-Cell Lymphoma: A Mendelian Randomization Analysis

  2024cites this paper
• Identification of malignant plasma cells in the primary mediastinal large B-cell lymphoma

  2024influential citation
• Molecular and Clinicopathologic Characterization of HER2-overexpressed Squamous Cell Carcinoma of the Cervix.

  2024cites this paper
• Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies

  2024cites this paper
• Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies

  2024cites this paper
• Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features

  2024cites this paper
• Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients

  2024cites this paper